Literature DB >> 20375651

Imatinib (Gleevec) as a paradigm of targeted cancer therapies.

Brian Druker1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375651     DOI: 10.2302/kjm.59.1

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


× No keyword cloud information.
  2 in total

Review 1.  Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

Authors:  Qingxin Mu; Jesse Yu; Lisa A McConnachie; John C Kraft; Yu Gao; Gaurav K Gulati; Rodney J Y Ho
Journal:  J Drug Target       Date:  2018-01-10       Impact factor: 5.121

Review 2.  Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.

Authors:  Natalie J Serkova; S Gail Eckhardt
Journal:  Front Oncol       Date:  2016-07-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.